
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics is expected to have a positive financial outlook due to its successful initiation of a new long-term extension study for patients who completed the Phase 2b study of Halneuron for CINP treatment, expected to report results in Q3 of 2026. With no drugs currently approved for this indication in the US, a positive outcome could lead to significant market share and a clear regulatory path. Additionally, the company is in discussions for potential partnerships and its upcoming clinical program SP16 for CIPN, which could also drive positive outcomes and potential upside for the stock.
Bears say
Dogwood Therapeutics is a development-stage biopharmaceutical company with no current revenue and a projected net loss of $0.56 per share for 2026. Additionally, their cash on hand is only enough to fund operations until 2Q27, which could present challenges in the future. These factors suggest a negative outlook for their stock.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares